Plain-English translation of NCT07163793 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether patients with acute myeloid leukemia (a serious blood cancer) who have achieved remission can safely take on a shorter 14-day cycle instead of the standard longer schedule. The medication will be combined with another drug you may have already received during your initial treatment. The goal is to see if giving the medication for fewer days each month reduces difficult side effects while still keeping your cancer in remission.
Current treatment schedules sometimes cause severe blood cell shortages that can be hard to manage. Researchers want to know if using this medication for a shorter time each month might be easier to tolerate while still working just as well to keep your cancer under control.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth for 14 days of each 28-day treatment cycle while continuing the other drug you received during your induction therapy. You will continue this routine treatment until your cancer returns, you experience a severe side effect that requires stopping the study, or another stopping point is reached. The study team will monitor your blood counts and overall health regularly to watch for side effects and how well the shorter schedule is working for you.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Northwell Health
Enrollment target
~41 participants
Started
October 2024
Primary completion
October 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Heme Referral Team
Northwell Health
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.